Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Company to Host Conference Call and Webcast on August 7, 2024
公司将于2024年8月7日举行电话会议和网络直播
LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.
美国东部时间2024年8月7日上午8:30（太平洋时间上午5:30），专注于发展和商业化mTOR通路突变癌症治疗方法的商业化精准肿瘤学公司Aadi Bioscience，Inc.（NASDAQ：AADI）今天宣布，将于2024年8月7日星期三举行电话会议和现场网络直播，报告2024年第二季度财务业绩并提供最新的企业更新。
Conference Call Information
Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.
电话会议信息
参与者可以在aadibio.com网站的“投资者新闻”页面上访问此次会议的网络直播。如需通过电话参加，请在此处提前注册: 电话会议注册(vevent.com)。注册后，所有电话参与者将收到一封确认电子邮件，其中详细说明如何加入电话会议，包括拨入号码以及可用于访问会议的唯一密码和注册者ID。会议呼叫和网络直播的重播将在网站上存档至少30天。
About Aadi Bioscience, Inc.
Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
关于Aadi Bioscience, Inc.
Aadi是一家商业化精准肿瘤学公司，专注于发展和商业化mTOR通路突变癌症的治疗方法，mTOR是细胞生长和癌症进展的关键调节因子。为了充分发挥mTOR的抑制作用，Aadi独特地将纳米粒子蛋白结合（nab）技术与强效的mTOR抑制剂西罗莫司相结合。Aadi已经获得FDA批准并商业化 FYARRO，该药用于治疗局部晚期无法切除或转移性恶性血管外上皮细胞瘤（PEComa）的成年患者。
Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi is also exploring nab-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs) of the lung, gastrointestinal tract and pancreas, and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on Aadi's development pipeline is available on the Aadi website at and connect with us on Twitter and LinkedIn.
Aadi正在探索在PRECISION1中利用nab-西罗莫司治疗恶性实体瘤，这是一项II期肿瘤独立的登记试验，针对运载酰胺结合纳米粒子的微粒（nab）技术，其发挥的威力是最先进的mTOR抑制剂西罗莫司不能相提并论的。Aadi还在两项针对难以治疗的mTOR驱动癌症的II期单病种试验中探索nab-西罗莫司: 肺，胃肠道和胰腺的神经内分泌肿瘤（NET）和晚期或复发的内膜型子宫内膜癌（EEC）与来曲唑联合治疗治疗。有关Aadi的开发管道的更多信息，请访问Aadi网站，并在Twitter和LinkedIn上与我们联系。
Contact:
[email protected]
联系方式：
[email protected]
SOURCE Aadi Bioscience
资料来源：Aadi Bioscience